VAXCYTE, INC. Interest Receivable, Current
VAXCYTE, INC. (PCVX) had Interest Receivable, Current of $21.36 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Nontrade Receivables, Current
us-gaap:InterestReceivableCurrent · last filed 2026-02-24
- 2025-12-31: Interest Receivable, Current $21.36M.
- 2024-12-31: Interest Receivable, Current $20.26M.
- 2024-09-30: Interest Receivable, Current $17.57M.
- 2024-06-30: Interest Receivable, Current $8.08M.
| Period end | Interest Receivable, Current |
|---|---|
| 2025-12-31 | $21.36M 10-K · filed 2026-02-24 |
| 2024-12-31 | $20.26M 10-K · filed 2026-02-24 |
| 2024-09-30 | $17.57M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $8.08M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $8.02M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $3.60M 10-K · filed 2025-02-25 |
| 2023-09-30 | $3.44M 10-Q · filed 2023-11-06 |
| 2022-12-31 | $2.85M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |